2025-523601-16-00RecruitingPhase 1
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Eli Lilly & Co.
- Enrollment
- 188
- Locations
- 16
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Eli Lilly & Co.
Scientific
Eli Lilly & Co.
Study Sites (16)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid ArthritisRheumatoid arthritis (RA)2025-523980-39-00Eli Lilly & Co.15
Recruiting
Phase 1
A Study of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver ImpairmentHealthy, Hepatic Insufficiency2025-521947-19-00Eli Lilly & Co.26
Recruiting
Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (FiREBOLT)Ovarian Neoplasms Breast Neoplasms Pancreatic Intraductal Neoplasms Colorectal Neoplasms Esophageal Neoplasms Stomach Neoplasms Cholangiocarcinoma2025-521887-37-00Eli Lilly & Co.64
Recruiting
Phase 1
A Phase 1 Study on the effects of LY3410738 (study drug) administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 MutationsPatients with IDH1 R132, IDH2 R140 or IDH2 R172-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma.2024-515150-24-00Eli Lilly & Co.3
Recruiting
Phase 1
A Phase 1 Study of PRT12396 in Participants with Select Myeloproliferative NeoplasmsPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera MyelofibrosisIntermediate-1, Intermediate-2, or High-Risk Primary MyelofibrosisHigh-risk Polycythemia Vera2026-525484-40-00Prelude Therapeutics Inc.22